StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Johnson & Johnson gets green light for lung cancer combination treatment
August 20, 2024 7:49 AM
Johnson & Johnson (NYSE: JNJ) announced Tuesday that it has received U.S. Food and Drug Administration (FDA) approval for a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Hot List
Next Articles
Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn
August 20, 2024 8:40 AM
Johnson & Johnson (JNJ) to Acquire V-Wave
August 20, 2024 7:30 AM
Johnson & Johnson to Acquire V-Wave
August 20, 2024 7:30 AM
J&J's chemotherapy-free treatment for lung cancer gets US approval
August 20, 2024 7:17 AM
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE approved in the U.S.
August 20, 2024 7:01 AM
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
August 20, 2024 7:00 AM
